Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Roche’s Tecentriq yields positive data in early stage NSCLC

Roche’s Tecentriq yields positive data in early stage NSCLC the dominant shadow of Merck &Co’s Keytruda (pembrolizumab). ... Keytruda has become a new standard-of-care for the treatment of newly-diagnosed NSCLC, although this immunotherapy failed to demonstrate the same benefit in SCLC.

NICE rejects Keytruda for advanced bladder cancer in final guidance

NICE rejects Keytruda for advanced bladder cancer in final guidance Following this rejection, MSD appealed the decision, although NICE has upheld its previous guidance not to recommend Keytruda as a second-line treatment for advanced bladder cancer patients. ... In a statement issued today, NICE said that although

FDA advisory committee to review oncology accelerated approvals

FDA advisory committee to review oncology accelerated approvals trials. However, continued approval in this indication was dependent on a post-marketing study demonstrating the superiority of Keytruda as determined by overall survival (OS). ... Keytruda failed to meet this requirement in the KEYNOTE-604 trial, as

Novartis’ canakinumab misses the mark in previously treated NSCLC

Novartis’ canakinumab misses the mark in previously treated NSCLC The CANOPY-1 study, evaluating canakinumab in combination with Merck &Co’s Keytruda (pembrolizumab) and chemotherapy in previously untreated NSCLC patients, could report final results before the end of the year.

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC Despite the NSCLC market being largely dominated by Merck &Co’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in around

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics